BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » history

Key Dates in the Discovery of Mesenchymal Stem Cells (MSCs)

August 25, 2017 By Cade Hildreth (CEO) Leave a Comment

nutristem | Top 5 Reasons to Use Biological Industries’ NutriStem® for Isolation and Growth of hMSCs

Mesenchymal stem cells (MSCs) have inspired a great deal of activity as a novel therapeutic approach. Presently, MSC-based clinical trials are being conducted for a variety of disease conditions, with many trials demonstrating safety and efficacy.

Clinical utility of MSCs can be attributed to four key biological properties:

  1. Their potential to migrate to sites of inflammation caused by tissue injury when injected intravenously
  2. Their potential to differentiate into different cell types
  3. Their potential to release different bioactive molecules that can stimulate the recovery of injured cells
  4. Their ability to modulate inflammation and accomplish immunomodulatory functions

Currently, several hundred MSC clinical trials are in progress across different parts of the world, including within the U.S. European Union (EU), China, Middle East, and South Korea. Among these clinical trials, approximately one-third are exploiting MSCs for various disease indications. Unfortunately, only a small number of clinical trials using MSCs have reached Phase III, indicating that the therapeutic potential for MSCs has yet to be realized.

One of the major bottlenecks to the industry is how to manufacture clinical-grade MSCs on a commercial scale, which Australian regenerative medicine company Cynata Therapeutics (ASX:CYP) is aiming to solve.

To fully understand the cell type and its evolution over time, this post considers key dates in the discovery of mesenchymal stem cells (MSCs). [Read more…]

Filed Under: MSCs, Stem Cells Tagged With: history, mesenchymal stem cells

Nanocellect

Marathon Products

Kimera Society

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram

Cart

Top Rated Products

  • Job Posting on BioInformant <Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience $297
  • U.S. Cord Blood Banking Survey <Cord Blood Banking Survey of U.S. Parents [2017] $197
  • Exosome Companies 2020 <Global Database of Exosome Companies $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.